Safety, Pharmacokinetics, and Plasmodium Falciparum Transmission-reducing Activity of Monoclonal Antibody TB31F in Mali
Status:
RECRUITING
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
Mali faces a significant challenge with malaria, particularly among its younger population. While existing measures like seasonal chemoprevention and vaccination have shown efficacy, further innovations are necessary to combat this disease. The monoclonal antibody TB31F shows promise in reducing the transmission of malaria. This clinical trial will evaluate the safety and efficacy of the monoclonal antibody TB31F.
Phase:
PHASE1
Details
Lead Sponsor:
Radboud University Medical Center
Collaborators:
London School of Hygiene and Tropical Medicine Malaria Research and Training Center, Bamako, Mali